Literature DB >> 8593442

Thrombolytic effect of nattokinase on a chemically induced thrombosis model in rat.

M Fujita1, K Hong, Y Ito, R Fujii, K Kariya, S Nishimuro.   

Abstract

Nattokinase is a new fibrinolytic enzyme which cleaves directly cross-linked fibrin in vitro. In this study, we investigated the thrombolytic effect of nattokinase on a thrombus in the common carotid artery of rat in which the endothelial cells of the vessel wall were injured by acetic acid. When a section of occluded vessel was stained for CD61 antigen by immunofluorescence utilizing a monoclonal antibody, the antigen was localized around the surface of the occluded blood vessels. This result suggests that the occlusive thrombosis was caused by platelet aggregation. In addition, thrombolysis with urokinase (UK; 50000 IU/kg, i.v.) or tissue plasminogen activator (tPA; 13300 IU/kg, i.v.) in our model was observed to restore the blood flow over a 60 min monitoring period. The results indicate that our chemically induced model is useful for screening and evaluating a thrombolytic agent. We evaluated the thrombolytic activity of nattokinase using this model and compared it with fibrino(geno)lytic enzyme, plasmin or elastase. On a molar basis, the recovery of the arterial blood flow with nattokinase, plasmin and elastase were 62.0 +/- 5.3%, 15.8 +/- 0.7% and 0%, respectively. The results indicate that the thrombolytic activity of nattokinase is stronger than that of plasmin or elastase in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593442     DOI: 10.1248/bpb.18.1387

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  24 in total

Review 1.  Traditional healthful fermented products of Japan.

Authors:  Yoshikatsu Murooka; Mitsuo Yamshita
Journal:  J Ind Microbiol Biotechnol       Date:  2008-05-07       Impact factor: 3.346

2.  Consequence of patient substitution of nattokinase for warfarin after aortic valve replacement with a mechanical prosthesis.

Authors:  Maqsood M Elahi; Charles H Choi; Subbareddy Konda; Jay G Shake
Journal:  Proc (Bayl Univ Med Cent)       Date:  2015-01

3.  The evolution of recombinant thrombolytics: Current status and future directions.

Authors:  Yogender Pal Khasa
Journal:  Bioengineered       Date:  2016-10-03       Impact factor: 3.269

4.  Comparative anti-thrombotic activity and haemorrhagic adverse effect of nattokinase and tissue-type plasminogen activator.

Authors:  Haiyu Guo; Young-Hwan Ban; Yeseul Cha; Eun Suk An; Jieun Choi; Da Woom Seo; Dongsun Park; Ehn-Kyoung Choi; Yun-Bae Kim
Journal:  Food Sci Biotechnol       Date:  2019-05-27       Impact factor: 2.391

Review 5.  Soy intake and chronic disease risk: findings from prospective cohort studies in Japan.

Authors:  Chisato Nagata
Journal:  Eur J Clin Nutr       Date:  2020-09-11       Impact factor: 4.016

6.  Purification and characterization of a fibrinolytic enzyme of Bacillus subtilis DC33, isolated from Chinese traditional Douchi.

Authors:  Cheng Tao Wang; Bao Ping Ji; Bo Li; Rob Nout; Ping Lan Li; Hong Ji; Long Fei Chen
Journal:  J Ind Microbiol Biotechnol       Date:  2006-03-31       Impact factor: 3.346

7.  Nattokinase-heparin exhibits beneficial efficacy and safety-an optimal strategy for CKD patients on hemodialysis.

Authors:  Hao Wu; Huan Wang; Wei Li; Chi Zhang; Yushan Liu; Feng Xu; Jiepeng Chen; Lili Duan; Fengjiao Zhang
Journal:  Glycoconj J       Date:  2019-02-20       Impact factor: 2.916

Review 8.  Fibrinolytic Enzymes for Thrombolytic Therapy.

Authors:  Swaroop S Kumar; Abdulhameed Sabu
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

9.  A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles.

Authors:  Yuko Kurosawa; Shinsuke Nirengi; Toshiyuki Homma; Kazuki Esaki; Mitsuhiro Ohta; Joseph F Clark; Takafumi Hamaoka
Journal:  Sci Rep       Date:  2015-06-25       Impact factor: 4.379

10.  Safety assessment of subtilisin QK in rats.

Authors:  Shuai Xiao; Dingbang Hu; Ya Gao; Yang Ai; Sang Luo; Song Chen; Ben Wang; Li Zhou; Yanshan Dong; Yefu Wang
Journal:  BMC Pharmacol Toxicol       Date:  2021-06-26       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.